• Dr. Clare Jones, CSO, speaking at disease modelling digital conference tomorrow.

    Talisman’s CSO, Dr. Clare Jones, is an invited speaker at the “Meet the Models” digital conference tomorrow starting at 1pm BST.

    Dr. Jones will be providing critical updates on disease models to accelerate …

    Read more
  • Talisman presents new data at ADPD 2023 in Sweden

    Dr. Clare Jones, Talisman CSO, was in attendance at the 2023 ADPD symposium in Sweden to present exciting new data on our fully human iPSC-derived cortical neuron/microglia co-cultures, showing robust neuroinflammatory signalling and …

    Read more
  • New publication: Predictive validity in drug discovery

    A key concern in pharmaceutical R&D is developing and using the best decision tools (e.g. models, assays) to advance disease knowledge and accurately assess therapeutic candidates. In the latest Perspectives review published recently …

    Read more
  • Human Stem Cell Model Development for Neurodegenerative Diseases

    How can the use of human stem cell models of neurodegenerative disease advance drug discovery?

    In this article hosted by Oxford Global, Dr. Clare Jones, Chief Scientific Officer at Talisman Therapeutics, outlines the …

    Read more
  • Human Stem Cell Models of Neurodegeneration: Exploiting In Vitro Phenotypes to Support Drug Delivery

    Human stem cell models offer invaluable insights into how neurodegenerative diseases such as Alzheimer’s and Parkinson’s affect the brain. In this article hosted by Oxford Global, Dr. Clare Jones, Chief Scientific Officer at …

    Read more
  • Talisman selected to participate at the Fast-Track Programme to Barcelona-Catalonia Life Science Hub

    Talisman Therapeutics is delighted to be one of 10 biotech and life sciences companies from the UK to have been selected to participate at the Fast-Track Programme to Barcelona-Catalonia Life Science Hub, Catalonia …

    Read more
  • Talisman presenting at the Biomarkers UK conference (8-9th November 2021)

    Dr. Clare Jones, Talisman’s CSO, will be speaking at the Biomarkers UK conference in Manchester next week (8-9th November 2021), introducing Talisman’s neurodegenerative disease modelling platforms and showcasing some recent work.

    Biomarkers UK …

    Read more
  • Talisman Therapeutics’ CSO, Dr. Clare Jones, presenting at Cambridge New Therapeutics Forum

    Talisman CSO, Dr. Clare Jones, will be speaking at the Cambridge New Therapeutics Forum tonight, giving a talk titled: “Use of human stem cell models of neurodegeneration to advance drug discovery”.

    Do come …

    Read more
  • Talisman presenting at Oxford Global’s Cell UK conference (28 – 29 October 2021)

    Talisman CSO, Dr. Clare Jones, will be speaking at the Cell UK conference in London next week (28 – 29 October 2021), giving a talk titled: “Use of human stem cell models of …

    Read more
  • Join us later at the at the PDDP virtual summit as Talisman Therapeutics’ CSO, Dr. Clare Jones, gives a keynote presentation!

    Talisman Therapeutics CSO, Dr. Clare Jones, will be presenting a key note talk titled “The use of human stem cell models of neurodegenerative disease to advance drug discovery” at the Precision in Drug …

    Read more